CIK cell therapy for liver cancer after surgery
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving immune cells called CIK cells can help prevent liver cancer from coming back after surgery. It is for people with early-stage liver cancer who have had their tumor removed and are currently cancer-free.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with early-stage liver cancer (BCLC stage 0 or A) and have had surgery to remove the tumor.
- You had either a single tumor or up to 3 nodules, each no larger than 3 cm.
- Your liver function is good (Child-Pugh score A or B) and you are physically active (ECOG score 0 or 1).
- One month after surgery, scans show no cancer remaining.
- You have not had any other cell therapy or immunotherapy in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (GKL-006) combined with a standard treatment called TACE (which blocks blood flow to the tumor) for people with liver cancer that cannot be removed by surgery. The goal is to see if adding this drug helps shrink tumors more than TACE alone.
This trial tests a new drug that combines two immunotherapy approaches (PD-1 and IL-2) given before surgery to treat hepatocellular carcinoma (liver cancer) that has come back 3 months to 2 years after your first surgery. The goal is to shrink the tumor and help your body's immune system fight the cancer.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This trial tests using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It may help if you have Barcelona Clinic Liver Cancer (BCLC) stage B or C and your liver function is still fairly good.
This trial tests CIK immune cells for children and young adults with B-cell acute lymphoblastic leukemia that stopped responding to CAR-T cell therapy within 6 months. The goal is to see if CIK cells can help when CAR-T cells no longer work.
This study tests an experimental therapy using your own natural killer cells to fight liver cancer. It may be an option if you have a specific stage of liver cancer and are generally in good health.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.